Literature DB >> 16430247

Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening.

Lennart Lindfors1, Pia Skantze, Urban Skantze, Mikael Rasmusson, Anna Zackrisson, Ulf Olsson.   

Abstract

Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.

Mesh:

Substances:

Year:  2006        PMID: 16430247     DOI: 10.1021/la0523661

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  24 in total

1.  Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state.

Authors:  Sneha Rathi; Rahul B Chavan; Nalini R Shastri
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization.

Authors:  Nilesh S Saindane; Kunal P Pagar; Pradeep R Vavia
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

3.  Nanosuspended branched chain amino acids: the influence of stabilizers on their solubility and colloidal stability.

Authors:  Chi Rac Hong; Gyu Whan Lee; Hyun-Dong Paik; Pahn-Shick Chang; Seung Jun Choi
Journal:  Food Sci Biotechnol       Date:  2017-05-29       Impact factor: 2.391

4.  Celecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluation.

Authors:  Anju Malkani; Abhijit A Date; Darshana Hegde
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

5.  Fabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability.

Authors:  Dnyanesh B Shelar; Smita K Pawar; Pradeep R Vavia
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

6.  Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.

Authors:  Dandan Liu; Heming Xu; Baocheng Tian; Kun Yuan; Hao Pan; Shilin Ma; Xinggang Yang; Weisan Pan
Journal:  AAPS PharmSciTech       Date:  2012-01-13       Impact factor: 3.246

Review 7.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

8.  Polymer-mediated anti-solvent crystallization of nitrendipine: monodispersed spherical crystals and growth mechanism.

Authors:  Dengning Xia; Mei Ouyang; Jian X Wu; Yanbo Jiang; Hongyu Piao; Shaoping Sun; Li Zheng; Jukka Rantanen; Fude Cui; Mingshi Yang
Journal:  Pharm Res       Date:  2011-07-12       Impact factor: 4.200

9.  Silver sulfadiazine nanosystems for burn therapy.

Authors:  Meenakshi Venkataraman; Mangal Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2012-12-29       Impact factor: 3.246

10.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.